Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Human epididymis protein 4 (HE4) has been suggested as a useful new biomarker of lung cancer; however, few relevant large-scale studies have been published. In this study, we evaluated the utility of serum HE4 for lung cancer detection. HE4 levels were measured in serum samples from 100 lung cancer patients, 57 patients with benign lung diseases, and 274 healthy controls by using a chemiluminescent immunoassay, and variations in HE4 levels were analyzed by clinical status such as lung cancer, benign lung disease, and healthy condition, Tumor, Lymph Nodes, Metastasis (TNM) stage, tumor score, and histological cancer type. Lung cancer patients had significantly higher serum HE4 levels than patients with benign lung diseases and healthy controls (P<0.0001). The area under the ROC curve for HE4 was 0.84 (95% confidence interval, 0.78–0.89; P<0.0001) between lung cancer patients and healthy controls. Serum HE4 levels were significantly higher in patients with advanced disease (according to TNM stage) than in healthy controls (P<0.0001). HE4 levels were significantly elevated in patients with tumors of all types, those of different histological subgroups, and those with the smallest tumors (P= 0.002). This report supports the potential of serum HE4 as an ancillary diagnostic marker for lung cancer detection,
Abstract
Human epididymis protein 4 (HE4) has been suggested as a useful new biomarker of lung cancer; however, few relevant large-scale studies have been published. In this study, we evaluated the utility of serum HE4 for lung cancer detection. HE4 levels were measured in serum samples from 100 lung cancer patients, 57 patients with benign lung diseases, and 274 healthy controls by using a chemiluminescent immunoassay, and variations in HE4 levels were analyzed by clinical status such as lung cancer, benign lung disease, and healthy condition, Tumor, Lymph Nodes, Metastasis (TNM) stage, tumor score, and histological cancer type. Lung cancer patients had significantly higher serum HE4 levels than patients with benign lung diseases and healthy controls (P<0.0001). The area under the ROC curve for HE4 was 0.84 (95% confidence interval, 0.78–0.89; P<0.0001) between lung cancer patients and healthy controls. Serum HE4 levels were significantly higher in patients with advanced disease (according to TNM stage) than in healthy controls (P<0.0001). HE4 levels were significantly elevated in patients with tumors of all types, those of different histological subgroups, and those with the smallest tumors (P= 0.002). This report supports the potential of serum HE4 as an ancillary diagnostic marker for lung cancer detection,
참고문헌 (19)
- "SEER Cancer Statistics Review, 1975-2012"[URL]
- Manser R, Lethaby A, "Cochrane database of systematic reviews 2013, Issue 6", pp.3~10 (2013), John Wiley & Sons, Ltd
- Tas F, "Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer", J Exp Clin Cancer Res, 19, pp.477~481 (2000)
- Brower V, "Biomarker studies abound for early detection of lung cancer", J Natl Cancer Inst, 101, pp.11~13 (2009)
- Hellström I, "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma", Cancer Res, 63, pp.3695~3700 (2003)
- Kong SY, "Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer", Ann Surg Oncol, 19, pp.1707~1712 (2012)
- Galgano MT, "Comprehensive analysis of HE4 expression in normal and malignant human tissues", Mod Pathol, 19, pp.847~853 (2006)
- Iwahori K, "Serum HE4 as a diagnostic and prognostic marker for lung cancer", Tumour Biol, 33, pp.1141~1149 (2012)
- Sobin LH, "TNM classification of malignant tumors" (2009), Wiley- Blackwell
- Galateau-Salle F, "The 2015 World Health Organization classification of tumors of the pleura: Advances since the 2004 classification", J Thorac Oncol, 11, pp.142~154 (2016)
- Thompson RC, "Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase", Proc Natl Acad Sci U S A, 83, pp.6692~6696 (1986)
- Wiedow O, "Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence", J Biol Chem, 265, pp.14791~14795 (1990)
- Devoogdt N, "Secretory leukocyte protease inhibitor in cancer development", Ann N Y Acad Sci, 1028, pp.380~389 (2004)
- Zhang M, "Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level", Cancer Res, 55, pp.2537~2541 (1995)
- Liu W, "Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis", Int J Tuberc Lung Dis, 17, pp.1346~1353 (2013)
- Nagy B Jr, "Elevated human epididymis protein 4 concentrations in chronic kidney disease", Ann Clin Biochem, 49, pp.377~380 (2012)
- Tang QF, "Value of serum marker HE4 in pulmonary carcinoma diagnosis", Int J Clin Exp Med, 8, pp.19014~19021 (2015)
- Escudero JM, "Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases", Clin Chem, 57, pp.1534~1544 (2011)
- Ferraro S, "Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review", J Clin Pathol, 66, pp.273~281 (2013)